Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 12:13:1041342.
doi: 10.3389/fgene.2022.1041342. eCollection 2022.

Editorial: Genetics of familial hypercholesterolemia: New insight-Volume II

Alpo Vuorio  1   2 , Uma Ramaswami  3   4 , Kirsten B Holven  5   6
Affiliations
Editorial

Editorial: Genetics of familial hypercholesterolemia: New insight-Volume II

Alpo Vuorio et al. Front Genet. .
No abstract available

Keywords: COVID-19; LDL; Lp(a); PCSK9 inhibitors; familial hypercholesterolemia; mutations; statins.

PubMed Disclaimer

Conflict of interest statement

AV has received consultation fees Amgen and Novartis, none of which are related to the content of this manuscript. KH has received research grants or honoraria from Mills AS, Tine SA, Olympic Seafood, Amgen, Sanofi, none of which are related to the content of this manuscript. The remaining author declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Genetics of familial hypercholesterolemia: New insight—volume II

References

    1. Bogsrud M. P., Græsdal A., Johansen D., Langslet G., Hovland A., Arnesen K. E., et al. (2019). LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of lp(a) in A large cohort of predominantly genetically verified familial hypercholesterolemia. J. Clin. Lipidol. 13 (2), 279–286. 10.1016/j.jacl.2019.01.010 - DOI - PubMed
    1. Chakraborty A., Pang J., Chan D. C., Ellis K. L., Hooper A. J., Bell D. A., et al. (2022). Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). Atherosclerosis 349, 219–226. 10.1016/j.atherosclerosis.2021.11.004 - DOI - PubMed
    1. Futema M., Ramaswami U., Tichy L., Bogsrud M. P., Holven K. B., Roeters van Lennep J., et al. (2020). Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis 292, 178–187. 10.1016/j.atherosclerosis.2019.11.012 - DOI - PMC - PubMed
    1. Gidding S. S., Wiegman A., Groselj U., Freiberger T., Peretti N., Dharmayat K. I., et al. (2022). Paediatric familial hypercholesterolaemia screening in europe – public policy background and recommendations. Eur. J. Prev. Cardiol., zwac200. 10.1093/eurjpc/zwac200 - DOI - PubMed
    1. Kronenberg F., Mora S., Stroes E. S. G., Ference B. A., Arsenault B. J., Berglund L., et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European atherosclerosis society consensus statement. Eur. Heart J. 29, ehac361. Epub ahead of print. PMID: 36036785. 10.1093/eurheartj/ehac361 - DOI - PMC - PubMed

Publication types